PFE

Summary

Hold existing PFE longs and do not chase new longs at 29.00. Risk/reward is balanced: volume-confirmed golden cross (29.00 > 28.21 > 25.61 > 25.40, VWMA 27.96, 59.8M breakout) and 6.02% yield support holding, but RSI 72.27, 0.28 below Bollinger Upper 29.28, flat MACD (0.85, hist 0.04 vs 0.88 Aug 26), and price 0.76% above target 28.60 / 99% of 52w high 29.09 argue against adding. Maintain core position, take partial profits if overweight and consider selling covered calls into put-demand richness. Risk levels: tight trail 28.21 (10 EMA) or 28.41 (1x ATR 0.59), position stop 27.58 (Bollinger mid) / 27.96 VWMA. Add only on pullback to 28.21-27.58 with RSI reset or confirmed close >29.28 on full volume targeting 29.6-29.9. Horizon is a 5-day tactical hold; we require Q3 FCF >2B and Depo charge disclosure before re-leveraging.

The case

Our analysis sees trend undeniably bullish but extremely extended, fundamentals solid on a normalized basis but GAAP/cash stressed at the margin, with price at resistance. RSI 63-77 persistence since Aug 6, price holding above 27.79 for 2 weeks after Aug 19 band break, VWMA confirmation, MACD still bullish without bear cross, and that impairments (4.325B Q2 + 4.47B Q4 = 8.8B on 118B goodwill, tangible book -33.2B) are non-cash vs TTM EBITDA 25.38B, FCF 12.48B (78% payout), 74.7% margin, 3.5B op income. Relative strength holding flat while BNTX -8% / MRNA -6% on mRNA failure and Sanofi RSV halt helping Abrysvo supports trend quality. Poor entry math remains: buying 2.8% above 10 EMA with ATR 0.59 implies 3% pullback to 28.12 on normal 1.5x ATR noise, MACD histogram compression, unfinished intraday print (29.00 on 7.7M vs 59.8M breakout, last settled close 28.55) risks bull trap wick at 29.28, put/call volume 1.97 (25,005 puts vs 12,725 calls) with a market fear gauge at 35.5 provides near-term convexity if 28.21 breaks, and Q2 FCF 302M vs 2.45B dividend funded by 4.38B investment sales shows quarterly coverage failure despite TTM cover. Depo-Provera 6k settlement removes overhang but charge unknown, COMIRNATY XFG is smaller high-risk market, Lyme PF-07307405 only EMA validation, and patent cliff 1.1B in 2026 accelerating to 2030 plus Aug 31 Medicaid pricing deals cap upside. The prior PFE Sell on 2026-08-27 failed (+3.1% alpha) by fading momentum on 0.14 buffer to 10 EMA and MACD compression without volume-confirmed close below 27.74/VWMA 27.42 - lesson: require volume-confirmed rejection before shorting. Neither chasing nor shorting has edge at 29.00: chasing risks immediate mean reversion, shorting fights primary trend with yield carry and hedge-unwind potential (OI 0.80 shows tactical not structural shorts). Hold is a positively concluded no-edge view, not an uncertainty default.

What would weaken it

• Overbought RSI 72.27 at Bollinger upper 29.28 risks pullback to 28.21
• Q2 FCF 302M vs 2.45B dividend funded by asset sales, coverage weak
• Patent cliff 1.1B in 2026 and Medicaid pricing deals cap upside